Chair Medical Cell BioPhysics - University of Twente
Leon pioneered the detection of rare cells and was in charge of the development of the CellSearch system, the only FDA cleared platform to enumerate circulating cancer cells in blood, which was awarded the “Prix Galien”, the major prize for in-vitro diagnostics devices. He is recipient of the Max Fulwyler Award for Innovative Excellence and is listed as an inventor of 53 issued USA patents. He was the coordinator of the EU FP7-Health, CTCTrap from 2012-2015 and the program leader of the STW Perspectief program Cancer-ID and co-leader of the EU IMI program CANCER-ID from 2015-2020. Research efforts within the MCBP laboratory are mainly focused on technology development that can improve the diagnosis and treatment of cancer patients.
Single cell technologies applied for COVID antibody and vaccine development
To discover the optimal treatment for cancer patients a technology is being developed in which the secretome of individual cancer cells can be assessed and the response to drugs evaluated. While research is being conducted at MCBP, the UT start-up VyCAP is developing and commercializing the technology. The same technology can be applied for COVID-19 in which B-lymphocytes from patients are isolated and probed for the production of anti-covid antibodies. The ability to isolate the cells producing the desired antibodies enables the unique opportunity to produce a cell line optimized for the production of anti-covid therapies.